Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.

Abstract	Factor X deficiency is an important complication of amyloidosis. It is associated with severe bleeding that is difficult to control with plasma or prothrombin complex concentrates. Splenectomy ameliorates the factor X deficiency, but achieving satisfactory haemostasis for this operation is problematic. We report that a new clotting concentrate, recombinant factor VIIa, readily controls bleeding and makes splenectomy feasible.
Authors	L Boggio, D Green
Journal	British journal of haematology (Br J Haematol) Vol. 112 Issue 4 Pg. 1074-5 (Mar 2001) ISSN: 0007-1048 [Print] England
PMID	11298609 (Publication Type: Case Reports, Journal Article)
Chemical References	Anticoagulants Recombinant Proteins Factor VIIIa
Topics	Amyloidosis (complications, surgery) Anticoagulants (therapeutic use) Factor VIIIa (therapeutic use) Factor X Deficiency (complications, drug therapy, surgery) Female Hemostasis, Surgical Humans Middle Aged Recombinant Proteins (therapeutic use) Splenectomy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!